Skip to content
Home/Companies/Pharma/InnoSyn
InnoSyn

InnoSyn

Pharma·Netherlands·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns InnoSyn?

InnoSyn is a Dutch Pharma company, currently owned by Merieux Equity Partners since 2023.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQNetherlands
SectorPharma
Websiteinnosyn.com

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022
AcuSurgical
AcuSurgical
Active
MedTechFrance· 2021

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns InnoSyn?

InnoSyn is currently owned by Merieux Equity Partners, through Mérieux Innovation 1, since 2023.

When did Merieux Equity Partners acquire InnoSyn?

Merieux Equity Partners acquired InnoSyn in 2023.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue